Fei Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fei Sun has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Bin Gao
Department of Endocrinology, Tangdu Hospital, Air Force Medical University, Xi’an, China
2 shared publications - Shengru Liang
Fourth Military Medical University (Air Force Medical University)
2 shared publications - Wencheng Zhang
Fourth Military Medical University (Air Force Medical University)
2 shared publications - Xinwen Yu
Fourth Military Medical University (Air Force Medical University)
2 shared publications - Aili Yang
Fourth Military Medical University (Air Force Medical University)
1 shared publication - Guohong Zhao
Department of Endocrinology, Tangdu Hospital, Air Force Medical University, Xi'an, 710038, Shaanxi Province, P. R. China.
1 shared publication
Latest Publications
- 3 October 2025
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 137 (7) , 665-675
Effects of low-dose growth hormone treatment on obesity: a meta-analysis of randomized controlled trials
Growth hormone (GH) reduces visceral adiposity, increases lean body mass, and improves the lipid profile in obese adults. However, high-dose GH regimens have been associated with frequent adverse effects. The efficacy and safety of low-dose GH treatment in obese individuals without GH deficiency remain unclear. This study aims to evaluate the effects of recombinant human growth hormone (rhGH) on body composition, lipid profile, glucose metabolism, and adverse events in this population. A systematic review and meta-analysis were conducted in accordance with the PRISMA statement. PubMed, Cochrane Library, and EMBASE databases were systematically searched up to December 2024. Eligible studies included randomized controlled trials (RCTs) involving obese individuals without GH deficiency, with at least one endpoint related to body composition, lipid profile, or glucose metabolism. The study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO, #CRD42023464234). A total of 10 RCTs involving 420 participants were included. The mean age of participants ranged from 18 to 65 years, and treatment durations varied from 4 to 72 weeks. Low-dose rhGH therapy resulted in a significant reduction in visceral adipose tissue (SMD: -0.34, 95%CI: -0.57 to -0.12, p = 0.003) and a significant increase in thigh muscle area (MD: 6.33 cm2, 95%CI: 1.72 to 10.95, p = 0.007) compared to placebo. Additionally, fasting glucose levels were modestly elevated (MD: 4.18 mg/dL, 95%CI: 0.68 to 7.67, p = 0.02). No serious adverse events were reported in association with low-dose rhGH treatment across the included studies. Low-dose rhGH therapy significantly reduces visceral fat and enhances thigh muscle mass in obese individuals without GH deficiency. These findings suggest that low-dose rhGH may offer therapeutic potential for sarcopenic obesity, warranting further investigation in larger, longer-term studies.
- 3 October 2025
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 137 (7) , 665-675
Effects of low-dose growth hormone treatment on obesity: a meta-analysis of randomized controlled trials
Growth hormone (GH) reduces visceral adiposity, increases lean body mass, and improves the lipid profile in obese adults. However, high-dose GH regimens have been associated with frequent adverse effects. The efficacy and safety of low-dose GH treatment in obese individuals without GH deficiency remain unclear. This study aims to evaluate the effects of recombinant human growth hormone (rhGH) on body composition, lipid profile, glucose metabolism, and adverse events in this population. A systematic review and meta-analysis were conducted in accordance with the PRISMA statement. PubMed, Cochrane Library, and EMBASE databases were systematically searched up to December 2024. Eligible studies included randomized controlled trials (RCTs) involving obese individuals without GH deficiency, with at least one endpoint related to body composition, lipid profile, or glucose metabolism. The study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO, #CRD42023464234). A total of 10 RCTs involving 420 participants were included. The mean age of participants ranged from 18 to 65 years, and treatment durations varied from 4 to 72 weeks. Low-dose rhGH therapy resulted in a significant reduction in visceral adipose tissue (SMD: -0.34, 95%CI: -0.57 to -0.12, p = 0.003) and a significant increase in thigh muscle area (MD: 6.33 cm2, 95%CI: 1.72 to 10.95, p = 0.007) compared to placebo. Additionally, fasting glucose levels were modestly elevated (MD: 4.18 mg/dL, 95%CI: 0.68 to 7.67, p = 0.02). No serious adverse events were reported in association with low-dose rhGH treatment across the included studies. Low-dose rhGH therapy significantly reduces visceral fat and enhances thigh muscle mass in obese individuals without GH deficiency. These findings suggest that low-dose rhGH may offer therapeutic potential for sarcopenic obesity, warranting further investigation in larger, longer-term studies.
- 3 October 2023
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 135 (7) , 741-749
Serum uric acid to high-density lipoprotein cholesterol ratio is a promising marker for identifying metabolic syndrome in nondiabetic Chinese men
To explore the relationship between serumuric acid (UA) to high-density lipoprotein cholesterol (HDL-C) ratio (UHR) and metabolicsyndrome (MetS) in nondiabetic individuals. A total of 15,760 nondiabetic participants were screened fromthe China National Diabetes and Metabolic Disorders Study. Pearson correlation wasused to determine the correlation between the components of MetS and UHR, HDL-C,and UA. Receiver operating characteristic curves were used to evaluate the abilityof UHR, HDL-C, and UA to identify MetS in the nondiabetic population. A total of 6,386 men and 9,374 women wereenrolled in this study. There were 1,480 (23.2%) men and 1,828 (19.5%) women withMetS. UHR significantly correlated with the components ofMetS in men and women, especially with waistcircumference and triglyceride. Inmen, although HDL-C showed a higher specificity index, UHR presented higher sensitivityindex and area under the curve (AUC) than HDL-C (P = 0.0001) and UA (P < 0.0001),with AUC (95% CI) of 0.762 (0.752-0.773). Higher AUCs of UHR relative to HDL-Cand UA were also observed in the age groups < 40 and 40-59 years. There was nosignificant difference in AUC between UHR and HDL-C in the age group ≥60 years (P = 0.370). However, similarresults were not observed in women. UHR could serve as a novel and reliablemarker for identifying the population at a high risk of MetS in nondiabetic men,especially in younger adults.
- 3 October 2023
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 135 (7) , 741-749
Serum uric acid to high-density lipoprotein cholesterol ratio is a promising marker for identifying metabolic syndrome in nondiabetic Chinese men
To explore the relationship between serumuric acid (UA) to high-density lipoprotein cholesterol (HDL-C) ratio (UHR) and metabolicsyndrome (MetS) in nondiabetic individuals. A total of 15,760 nondiabetic participants were screened fromthe China National Diabetes and Metabolic Disorders Study. Pearson correlation wasused to determine the correlation between the components of MetS and UHR, HDL-C,and UA. Receiver operating characteristic curves were used to evaluate the abilityof UHR, HDL-C, and UA to identify MetS in the nondiabetic population. A total of 6,386 men and 9,374 women wereenrolled in this study. There were 1,480 (23.2%) men and 1,828 (19.5%) women withMetS. UHR significantly correlated with the components ofMetS in men and women, especially with waistcircumference and triglyceride. Inmen, although HDL-C showed a higher specificity index, UHR presented higher sensitivityindex and area under the curve (AUC) than HDL-C (P = 0.0001) and UA (P < 0.0001),with AUC (95% CI) of 0.762 (0.752-0.773). Higher AUCs of UHR relative to HDL-Cand UA were also observed in the age groups < 40 and 40-59 years. There was nosignificant difference in AUC between UHR and HDL-C in the age group ≥60 years (P = 0.370). However, similarresults were not observed in women. UHR could serve as a novel and reliablemarker for identifying the population at a high risk of MetS in nondiabetic men,especially in younger adults.